Mind Medicine MindMed

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mind Medicine (MNMD) reports robust financials and advances in psychedelic research

Mind Medicine (MNMD) showcased strong financials, R&D progress, and strategic advancements in its Q4 2022 earnings call.
The company's focus on safety, responsible distribution, and talent acquisition positions it well for future growth and innovation.
Challenges in patient enrollment, dosing strategies, and commercialization strategies require strategic planning and clear execution for success.

Mind Medicine (MNMD) reports positive trial data and strong financials

Mind Medicine (MNMD) showcases progress in pipeline development with positive trial results and a strong financial position. The company's focus on advancing treatments for brain health disorders and efficient cash management highlights its commitment to growth and innovation.

MindMed (MNMD) reports Q2 loss, progresses on innovative treatments

MindMed (MNMD) is advancing its R&D pipeline with a focus on MM-120 for GAD and MM-402 for Autism spectrum disorder. Financially, the company maintains a strong position with cash reserves for ongoing operations. Emphasis on placebo-controlled research and innovative formulation technologies highlights a commitment to scientific rigor and product development.

Mind Medicine (MNMD) reports strong financials and promising R&D progress

Mind Medicine (MNMD) is making significant strides in developing innovative treatments for mental health disorders, with promising lead candidates MM-120 and MM-402. While facing increased R&D expenses and analyst scrutiny, the company's strong financial position and focus on unmet needs present opportunities for future growth.

MindMed reports positive Phase IIb results for MM120 in GAD

MindMed's financial performance in 2023 reflected a net loss of $95.7 million but maintained a strong cash position of $99.7 million.
The Phase IIb trial results for MM120 in GAD were positive, demonstrating significant reductions in HAM-A scores and high clinical response rates.
While facing challenges in trial design and demonstrating drug effects, MindMed remains focused on innovation and addressing unmet medical needs.
Opportunities lie in expanding product indications, developing new therapies, and engaging with regulatory authorities to advance their pipeline.

MindMed reports strong Q1 earnings, advances transformative treatments

MindMed's financials remain strong with significant cash reserves and positive trial outcomes for MM-120.
Strategic focus on advancing MM-120 and MM-402 programs while exploring market dynamics and treatment expansion.
Challenges include managing expenses to sustain financial health and interpreting trial data for future research.
Opportunities lie in exploring additional indications, commercial planning, and reshaping patient care with transformative treatments.

MindMed reports strong Q2 earnings, advances Phase III programs

Mind Medicine (MNMD) showcased strong performance in Phase III programs, fundraising, and financials, positioning the company well for future growth and clinical advancements.
With a focus on operational efficiency, patient recruitment, and data integrity, MindMed is poised to address unmet needs in brain health disorders and drive market expansion.
Challenges lie in meeting upcoming milestones, global market analysis, and maintaining data integrity in Phase III trials, but opportunities abound in R&D expansion and market penetration strategies.
Overall, MindMed's strategic focus on Phase III trials, regulatory pathways, and market launch strategies sets a clear path for future success and growth in the brain health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Mind Medicine (MindMed (NASDAQ:MNMD, NEO:MMED)) has announced encouraging results from its Phase 2b clinical trial of MM-120 in treating Generalized Anxiety Disorder (GAD). MM-120, a single-dose lysergide d-tartrate, demonstrated statistically significant and clinically meaningful improvements over placebo at Week 4, meeting its primary endpoint.

Mind Medicine's MM-120 shows promise in Phase 2b trial for Generalized Anxiety Disorder

Mind Medicine Inc. MNMD, +3.53% said Thursday a Phase 2 trial testing LSD as a treatment for generalized anxiety disorder met its main goal, showing a statistically significant improvement in scores by week four compared to placebo. The trial of MM-120 was administered as a single dose in a monitored clinical setting with no additional therapeutic intervention.

MindMed announces positive results in trial of LSD as a treatment for generalized anxiety disorder

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD). The trial met its primary endpoint, with MM-120 demonstrating statistically significant and clinically meaningful dose-depende.

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Rob Barrow - Chief Executive Officer Schond Greenway - Chief Financial Officer Dr. Dan Karlin - Chief Medical Officer Dr. Francois Lilienthal - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Francois Brisebois - Oppenheimer Jonathan Aschoff - ROTH MKM Operator Good afternoon, and welcome to the Mind Medicine Third Quarter 2023 Financial Results and Corporate Update Conference Call. Currently, all participants are in listen-only mode.

Mind Medicine (MindMed) Inc. (MNMD) Q3 2023 Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed today reported its financial results for the quarter ended September 30, 2023.

MindMed Reports Third Quarter 2023 Financial Results and Business Highlights

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET.

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update

NEW YORK--(BUSINESS WIRE)---- $MNMD--Enrollment completed for MMED007, the Phase 2a study evaluating repeated low-dose administration of MM-120 for the treatment of adults with ADHD.

MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Results from the phase 2b study, using MM-120 for the treatment of patients with generalized anxiety disorder, expected Q4 of 2023. The Generalized Anxiety Disorder market is set to reach $7.4 billion in 2023. Results from phase 2a proof-of-concept study, using MM-120 for the treatment of patients with ADHD, expected Q4 2023 or Q1 of 2024.

Mind Medicine: Q4 Of 2023 Data For GAD Makes This Worth A Look

Axcella Health Inc

Novavax

Pharma stocks and the biotech sector can offer explosive gains. It also offers incredibly crushing defeats in which share prices decline precipitously.

3 Pharma Stocks to Dump Before the Damage Is Done

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will present preclinical data for MM-402 in a model for autism spectrum disorder.

MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit.

MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed has completed enrollment and dosing in Study MMED008, the Phase 2b study evaluating MM-120 (lysergide D-tartrate) for the treatment of GAD.

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

NEW YORK--(BUSINESS WIRE)---- $MNMD--The MindMed management team will participate in two September investor conferences.

MindMed to Participate at September Investor Conferences

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed has entered into a senior secured credit facility with K2 HealthVentures, a healthcare-focused specialty finance company.

MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures

Mind Medicine Inc. (NASDAQ:MNMD ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Rob Barrow - Chief Executive Officer Schond Greenway - Chief Financial Officer Dan Karlin – Chief Medical Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Navin Jacob - RBC Capital Elemer Piros - EF Hutton Francois Brisebois – Oppenheimer Jonathan Aschoff - ROTH MKM Operator Good afternoon, and welcome to the Mind Medicine Second Quarter 2023 Financial Results and Corporate Update Conference call. Currently, all participants are in listen-only mode.

Mind Medicine Inc. (MNMD) Q2 2023 Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed today reported its financial results for the quarter ended June 30, 2023.

MindMed Reports Second Quarter 2023 Financial Results and Business Highlights

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed has entered into a license agreement to access Catalent's proprietary Zydis® orally disintegrating tablet (ODT) technology.

MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will provide a corporate update and review the Company's results for the quarter ended June 30, 2023.

MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update

COMPASS Pathways

GH Research PLC

Psychedelic stocks have a bright future with 13.5% compound annual growth expected through 2029. That growth will certainly draw in investment funding that seeks to capitalize on growth, as psychedelic drugs quickly  become a hot topic in the mental health space.

The 3 Best Psychedelic Stocks to Buy Now

As part of the renewed interest in the potential health applications of psychedelics in recent years, companies ranging from biotechnology startups to pharmaceutical giants are conducting ground-breaking clinical trials involving a range of psychedelic compounds including psilocybin, MDMA, and LSD. The results of these trials will likely create more innovative treatments for a range of physical and mental health conditions.

Psychedelic clinical trials: A glimpse at hotly-anticipated upcoming results

NEW YORK--(BUSINESS WIRE)---- $MNMD--Members of MindMed's management team will participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference on Monday, June 26.

MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed Announces Election of All Six Company Nominees at Annual Meeting.

MindMed Announces Election of All Six Company Nominees at Annual Meeting

Atai Life Sciences BV

Cybin

Blake Mycoskie, founder of the canvas-footwear phenomenon TOMS Shoes, has committed to giving $100 million to support psychedelic research and access, Mycoskie told MarketWatch in an exclusive interview. The money will help fund academic institutions investigating psychedelics' potential to treat anxiety, depression, post-traumatic stress disorder and other mental-health issues, as well as nonprofits helping to connect patients in need with psychedelic treatments.

TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will provide an overview of clinical progress and corporate updates, focused primarily on the MM-120 program for GAD.

MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day

NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed Adjourns Annual General Meeting of Shareholders.

News for Mind Medicine MindMed Stock (MNMD)